Yu X - Search Results

1

The TLK1-Nek1 axis promotes prostate cancer progression.

Singh V, Jaiswal PK, Ghosh I, Koul HK, Yu X, De Benedetti A. Singh V, et al. Among authors: yu x. Cancer Lett. 2019 Jul 1;453:131-141. doi: 10.1016/j.canlet.2019.03.041. Epub 2019 Mar 27. Cancer Lett. 2019. PMID: 30928383 Free article.

2

Targeting the TLK1/NEK1 DDR axis with Thioridazine suppresses outgrowth of androgen independent prostate tumors.

Singh V, Jaiswal PK, Ghosh I, Koul HK, Yu X, De Benedetti A. Singh V, et al. Among authors: yu x. Int J Cancer. 2019 Aug 15;145(4):1055-1067. doi: 10.1002/ijc.32200. Epub 2019 Feb 25. Int J Cancer. 2019. PMID: 30737777 Free PMC article.

3

The spectrum of neuroendocrine differentiation in prostate cancer.

Cheng S, Yu X. Cheng S, et al. Among authors: yu x. Prostate Cancer Prostatic Dis. 2021 Dec;24(4):1214-1215. doi: 10.1038/s41391-021-00386-5. Epub 2021 May 18. Prostate Cancer Prostatic Dis. 2021. PMID: 34007018 No abstract available.

4

The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer.

Cheng S, Prieto-Dominguez N, Yang S, Connelly ZM, StPierre S, Rushing B, Watkins A, Shi L, Lakey M, Baiamonte LB, Fazili T, Lurie A, Corey E, Shi R, Yeh Y, Yu X. Cheng S, et al. Among authors: yu x. Prostate Cancer Prostatic Dis. 2020 Dec;23(4):661-669. doi: 10.1038/s41391-020-0229-z. Epub 2020 Apr 20. Prostate Cancer Prostatic Dis. 2020. PMID: 32313141 Free PMC article.

5

Wnt/Beta-Catenin Signaling and Prostate Cancer Therapy Resistance.

Yeh Y, Guo Q, Connelly Z, Cheng S, Yang S, Prieto-Dominguez N, Yu X. Yeh Y, et al. Among authors: yu x. Adv Exp Med Biol. 2019;1210:351-378. doi: 10.1007/978-3-030-32656-2_16. Adv Exp Med Biol. 2019. PMID: 31900917 Review.

6

The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth.

Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, Case TC, Ellwood-Yen K, Sawyers CL, Bhowmick NA, Blackwell TS, Yull FE, Matusik RJ. Jin RJ, et al. Among authors: yu x. Cancer Res. 2008 Aug 15;68(16):6762-9. doi: 10.1158/0008-5472.CAN-08-0107. Cancer Res. 2008. PMID: 18701501 Free PMC article.

7

Identification of Genes Required for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells In Vitro.

Kohrt SE, Awadallah WN, Phillips RA 3rd, Case TC, Jin R, Nanda JS, Yu X, Clark PE, Yi Y, Matusik RJ, Anderson PD, Grabowska MM. Kohrt SE, et al. Among authors: yu x. Mol Cancer Ther. 2021 Feb;20(2):398-409. doi: 10.1158/1535-7163.MCT-20-0244. Epub 2020 Dec 9. Mol Cancer Ther. 2021. PMID: 33298586 Free PMC article.

8

Neuroendocrine prostate cancer has distinctive, non-prostatic HOX code that is represented by the loss of HOXB13 expression.

Cheng S, Yang S, Shi Y, Shi R, Yeh Y, Yu X. Cheng S, et al. Among authors: yu x. Sci Rep. 2021 Feb 2;11(1):2778. doi: 10.1038/s41598-021-82472-1. Sci Rep. 2021. PMID: 33531604 Free PMC article.

9

Skp2 regulates androgen receptor through ubiquitin-mediated degradation independent of Akt/mTOR pathways in prostate cancer.

Li B, Lu W, Yang Q, Yu X, Matusik RJ, Chen Z. Li B, et al. Among authors: yu x. Prostate. 2014 Apr;74(4):421-32. doi: 10.1002/pros.22763. Epub 2013 Dec 17. Prostate. 2014. PMID: 24347472 Free PMC article.

10

Mouse models of prostate cancer: picking the best model for the question.

Grabowska MM, DeGraff DJ, Yu X, Jin RJ, Chen Z, Borowsky AD, Matusik RJ. Grabowska MM, et al. Among authors: yu x. Cancer Metastasis Rev. 2014 Sep;33(2-3):377-97. doi: 10.1007/s10555-013-9487-8. Cancer Metastasis Rev. 2014. PMID: 24452759 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

32,068 results

Search Page